article thumbnail

How to get acquisition ready – a seller’s guide to merger and acquisition in pharma

pharmaphorum

M&A is an integral part of the lifecycle of pharma companies and a key strategy to future-proof larger players, driving R&D activities and innovation for a competitive product pipeline. Since the first wave of consolidation started in 1988, there has been a significant concentration of the pharma industry.

Pharma 104
article thumbnail

Unleash the Power of AI in GxP Manufacturing

PharmaTech

In pursuit of increased competitiveness and bottom-line impact, pharmaceutical manufacturers face increasing pressure to fast-track technological innovation while maintaining regulatory compliance. technology initiatives.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Should we be worried about pharma’s supply chain?

World of DTC Marketing

QUICK READ: Pharma supply chain issues are a concern for us all but especially patients. Hedley Rees has written a book on pharma supply chains that is eye-opening and downright scary. Can patients really be confident in pharma supply chains? Why would a pharma company take risks like these? Patients should be scared.

article thumbnail

Joint investment to accelerate UK sustainable biomanufacturing

European Pharmaceutical Review

UKRI highlighted that overall, these investments will “enhance the UK’s global competitiveness by supporting research and innovation that leads to new and disruptive biomanufacturing processes across the UK.” Curious about sustainability in pharmaceutical manufacturing and the supply chain?

article thumbnail

Top 5 Emerging Trends in Pharma Industry

Medico Reach

The Grand View Research published a report highlighting the stark growth prospects of the pharma industry. The global pharmaceutical manufacturing market stood at USD 405.52 The paradigm shift towards integrated, intelligent, and data-rich technologies is propelling the growth of medicines manufacturing. Let’s find out!

Pharma 52
article thumbnail

US legislative update: takeaways for European pharma

European Pharmaceutical Review

Pharmaceutical manufacturers have submitted Citizen Petitions raising safety or efficacy concerns about proposed competing generic and biosimilar products, and such submissions often delay FDA approval of the proposed products while the FDA resolves the pending petitions.

article thumbnail

Is the pharmaceutical sector realising its potential for sustainable manufacturing?

European Pharmaceutical Review

Globally, the pharmaceutical sector emitted around 52 megatonnes of CO 2 in 2015, the most recent period for which detailed numbers are available. 1 Every major pharmaceutical manufacturer in the UK and Ireland is investing in making their operations and supply chains more environmentally friendly.